Ignyta’s Drug Pipeline
Ignyta (RXDX) has completed enrollment for a Phase 1 clinical trial of RXDX-105, an orally bioavailable small molecule tyrosine kinase inhibitor.
Inside Ignyta’s Financial Performance
Ignyta’s (RXDX) R&D (research and development) expenses increased from $16.6 million in 3Q16 to $21.7 million in 3Q17, a 30% rise.
Ignyta and Its Key Risks in 2018
In October 2017, Ignyta (RXDX) raised $150 million by issuing 10 million shares of its common stock.
Analyzing Roche’s Acquisition of Flatiron Health
Raxibacumab has orphan drug designation in the US and was approved by the FDA in 2012.
What Led to Arrowhead Pharmaceuticals’ Revenue Surge in 2017?
Arrowhead Pharmaceuticals’ therapeutic candidate ARO-LUNG1 is being developed for an undisclosed disease of the lung. This is the first candidate to utilize the company’s TRiM platform.
Arrowhead’s Candidates for Hepatitis B, Cardiovascular Diseases
ARO-HBV is Arrowhead Pharmaceuticals’ (ARWR) investigational drug candidate for treating chronic hepatitis B infection.
Taking a Closer Look at Arrowhead Pharmaceuticals’ TRIM Platform
Arrowhead Pharmaceuticals’ (ARWR) prior efforts were aimed at clinical programs that utilized the dynamic polyconjugate (or DPC), also called the EX1 delivery vehicle.